Crispina Calsada Net Worth

The estimated Net Worth of Crispina Calsada is at least $472 mil dollars as of 18 January 2024. Ms Calsada owns over 5,468 units of Regulus Therapeutics Inc stock worth over $8,904 and over the last 5 years she sold RGLS stock worth over $6,507. In addition, she makes $456,650 as Chief Financial Officer at Regulus Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Calsada RGLS stock SEC Form 4 insiders trading

Ms has made over 1 trades of the Regulus Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 5,468 units of RGLS stock worth $6,507 on 18 January 2024.

The largest trade she's ever made was selling 5,468 units of Regulus Therapeutics Inc stock on 18 January 2024 worth over $6,507. On average, Ms trades about 497 units every 0 days since 2019. As of 18 January 2024 she still owns at least 5,782 units of Regulus Therapeutics Inc stock.

You can see the complete history of Ms Calsada stock trades at the bottom of the page.

Ms. Crispina Calsada biography

Crispina Calsada is the Chief Financial Officer at Regulus Therapeutics Inc.

What is the salary of Ms Calsada?

As the Chief Financial Officer of Regulus Therapeutics Inc, the total compensation of Ms Calsada at Regulus Therapeutics Inc is $456,650. There are 4 executives at Regulus Therapeutics Inc getting paid more, with Joseph Hagan having the highest compensation of $2,014,280.

How old is Ms Calsada?

Ms Calsada is 50, she's been the Chief Financial Officer of Regulus Therapeutics Inc since . There are 12 older and 2 younger executives at Regulus Therapeutics Inc. The oldest executive at Regulus Therapeutics Inc is David Baltimore, 82, who is the Independent Director.

What's Ms Calsada's mailing address?

Crispina's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS, 4224 CAMPUS POINT COURT #210, SAN DIEGO, CA, 92121.

Insiders trading at Regulus Therapeutics Inc

Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.

What does Regulus Therapeutics Inc do?

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Complete history of Ms Calsada stock trades at Regulus Therapeutics Inc

Regulus Therapeutics Inc executives and stock owners

Regulus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Hagan,
  President, Chief Executive Officer, Director
• Joseph P. Hagan M.B.A.,
  Pres, CEO & Director
• Christopher Aker,
  Senior Vice President, General Counsel
• Christopher Ray Aker J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Crispina Calsada,
  Chief Financial Officer
• Crispina Calsada,
  Chief Financial Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Pascale Witz,
  Independent Director
• Simos Simeonidis,
  Independent Director
• Hugh Rosen,
  Independent Director
• William Rastetter,
  Independent Director
• Jake Nunn,
  Independent Director
• Kathryn Collier,
  Independent Director
• David Baltimore,
  Independent Director
• Denis Drygin,
  Chief Scientific Officer
• Firuz Shakoori,
  Head of CMC
• Turner Jenkins,
  Sr. Director of Corp. Devel.
• Dr. Denis Drygin Ph.D.,
  Chief Scientific Officer
• Daniel J. Penksa,
  Controller & Principal Accounting Officer
• Jason Raleigh Nunn,
  
• Daniel R. Chevallard,
  Chief Financial Officer
• Paul C Grint,
  President & CEO
• Douglas E Williams,
  Director
• Mark Albert Deeg,
  Chief Medical Officer
• Pharmaceuticals, Inc. Alnylam,
  10% owner
• Mark G Foletta,
  Director
• Timothy Michael Wright,
  Chief R & D Officer
• Alexander J Sarissa Capital...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• David Leslie Szekeres,
  Chief Business Officer & GC
• Paul Edward Walker,
  
• Peter J Barris,
  10% owner
• Anthony A. Jr. Florence,
  
• Scott D Sandell,
  
• David M Mott,
  10% owner
• Mohamad Makhzoumi,
  
• Equity Opportunities V, Llc...,
  
• Ali Behbahani,
  
• Neil W Gibson,
  Chief Scientific Officer
• Pharmaceuticals Incparshall...,
  
• Kleanthis G Xanthopoulos,
  President and CEO
• Pharmaceuticals Inc Ionis,
  10% owner
• Bruce L A Carter,
  Director
• Barry E Greene,
  Director
• Sanofi,
  10% owner
• B Lynne Parshall,
  Director
• Stanley T Crooke,
  Director
• John Maraganore,
  Director
• Garry E Menzel,
  COO & Executive VP, Finance
• Forest Baskett,
  
• Carmen Chang,
  
• Joshua Makower,
  
• Peter W. Sonsini,
  
• Capital Offshore Master Fun...,
  10% owner
• Alice Shih Hou Baltimore Da...,
  
• Alice Shih Hou Huang,
  
• Preston Klassen,
  President & Head of R & D